Tech at Polsky
This technology generates antigen specific immune tolerance for autoimmune or transplantation therapy via induction of tolerogenic dendritic cells (tolDC, PD-L1+, CD80- CD11c+)) which facilitate the differentiation of antigen specific Tregs.
The invention is a liposome loaded with immunosuppressive drugs, toll-like-receptor (TLR) agonists, and any antigen of interest. This unique co-formulation of activating and inhibitory signals generates a potent toIDC phenotype in vivo.
Reliable generation of antigen specific Tregs with minimal non-specific immune suppression
Long-lived immune tolerance
Easy manufacturing and storage
February 7, 2022
Proof of concept
Reference ID 22-T-003
Contact Michael Hinton, Manager, Technology Marketing, who can provide more detail about this technology, discuss the licensing process, and connect you with the inventor.